GP Care is delighted to announce that the Community DVT Service has won 3rd prize at the Thrombus Innovation Awards for the second year running. The awards are designed to highlight projects that demonstrate innovation and excellence in any field of thrombosis care that can show real benefits; in this case, GP Care was given an award for the Rivaroxaban pathway that was introduced in April 2013.
Following NICE approval of Rivaroxaban as an oral anticoagulant for patients with deep vein thrombosis (DVT), GP Care developed a safe and alternative pathway to the existing warfarin pathway. The aims of introducing the Rivaroxaban pathway were:
- Benefits to patients;
- Greater treatment choice;
- Less impact on daily life;
- More independence;
- Less time at GP Surgeries;
- Further cost benefits to the NHS;
- Development of working relationships with primary and secondary care.
Since April 2013, 84% of patients on the GP Care pathway have chosen to be treated with Rivaroxaban.
Annie Kelly, Operations Director, was joined by the Service Lead, Lina Middleton and the patient co-ordinator, Lucy Stanley, to accept the prize at the award ceremony held at the BMA House, Tavistock Square, London. It was a well-attended event giving the opportunity to meet others working in the VTE/Anticoagulation field as well as listening to guest speaker Dr Steve Kitchen - Scientific Director of the UK NEQAS for Blood Coagulation.
(Left to right: Lina Middleton, Lucy Stanley and Annie Kelly)